Company DescriptionBrainCool AB (publ), a medical device company, together with its subsidiaries, engages in the development, marketing, and sale of medical cooling systems for the healthcare sector in Sweden. The company offers products for medical cooling treatments for a range of diseases, including stroke, sudden cardiac arrest, oral mucositis, and migraine. It provides BrainCool and RhinoChill systems that facilitates rapid medical cooling treatment in an emergency setting and ensures the continuum of care; Cooral system provides medical professionals an easy way to reduce the risk of oral mucositis; and IQool system offers an easy-to-use intuitive interface, informative graphics, and an automatic feedback loop allowing clinicians to manage their patient rather than a device. The company was incorporated in 2010 and is based in Lund, Sweden.

How the Company Makes Money

BrainCool AB Financial Statement Overview

Summary

BrainCool AB demonstrates strong revenue growth but faces challenges in profitability and cash flow generation. The balance sheet reflects a robust equity position, but the lack of profitability and negative cash flows represent risks that need to be addressed to ensure sustainable growth and financial stability.

Income Statement

Neutral

BrainCool AB shows significant revenue growth from 2019 to 2024, but continues to incur large net losses, with a negative EBIT and EBITDA margin. The revenue growth rate is promising, but the company is struggling with profitability, as indicated by negative gross and net profit margins.

Balance Sheet

Neutral

The company maintains a strong equity base and no debt, resulting in a favorable debt-to-equity ratio. However, continuous losses are a concern for long-term sustainability. The equity ratio indicates a strong asset base supported by equity, but the company must manage its liabilities effectively to improve financial stability.

Cash Flow

Negative

BrainCool AB's cash flow is under pressure with negative free cash flow and operating cash flow over the years, despite stable financing cash flow. The company's reliance on external financing raises concerns about its ability to generate cash organically, which is critical for its long-term financial health.

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
39.96M	23.23M	17.59M	9.26M	7.03M
	Gross Profit
13.13M	12.12M	-46.16M	-48.93M	-36.74M
	EBIT
-42.19M	-54.16M	-48.59M	-51.10M	-38.91M
	EBITDA
-34.06M	-49.86M	-35.07M	-32.16M	-30.39M
	Net Income Common Stockholders
-44.04M	-61.28M	-45.61M	-38.75M	-37.30M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
31.40M	25.06M	41.21M	13.58M	12.02M
	Total Assets
162.04M	133.28M	133.67M	99.35M	94.28M
	Total Debt
0.00	0.00	0.00	35.00M	0.00
	Net Debt
-31.40M	-25.06M	-41.21M	21.42M	-12.02M
	Total Liabilities
16.11M	21.54M	17.44M	54.12M	33.58M
	Stockholders Equity
145.93M	111.74M	116.23M	45.23M	60.70M
Cash Flow		Free Cash Flow
-70.20M	-67.23M	-53.67M	-35.06M	-46.82M
	Operating Cash Flow
-62.64M	-61.16M	-46.27M	-24.25M	-39.25M
	Investing Cash Flow
-7.57M	-6.17M	-7.59M	-10.82M	-8.37M
	Financing Cash Flow
76.80M	50.93M	81.28M	36.39M	46.57M

BrainCool AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
5YL		€35.98M	―	-33.54%	―	―	―
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
6Y1		€39.23M	―	-19.17%	―	―	―
3F8		€28.33M	―	-159.24%	―	―	―
7AC		€23.21M	―	-88.97%	―	―	―
1DO		€54.06M	―	-48.55%	―	―	―
MN2		€48.41M	―	-17.16%	―	―	―

* Healthcare Sector Average

Performance Comparison

DE:5YL

BrainCool AB

0.12

-0.08

-40.00%

DE:6Y1

Integrum AB Class B

1.79

-2.84

-61.34%

DE:3F8

Q-linea AB

0.04

0.02

100.00%

DE:7AC

Acarix AB

0.01

-0.01

-50.00%

DE:1DO

Doxa AB

0.01

-0.08

-88.89%

DE:MN2

Mentice AB

1.85

-0.52

-21.94%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.